TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15253739

Group type: EXPERIMENTAL
Intervention: Vitamin C (300 mg, intravenous sodium ascorbate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 60
Study: 11291823

Group type: EXPERIMENTAL
Intervention: Hybrid formats (digits and letters)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Embedding both geographical and organizational information
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Embedding both geographical information and organizational information
Number of subjects: 85
Study: 9815661

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8282473

Group type: EXPERIMENTAL
Intervention: CBORT
Number of subjects: 463

Group type: COMPARATOR
Intervention: GORS
Number of subjects: 463

Group type: COMPARATOR
Intervention: CBORS
Number of subjects: 463
Study: 2881320

Group type: EXPERIMENTAL
Intervention: 0.02 mcg/kg CCK‐8
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.04 mcg/kg CCK‐8
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study: 31062131

Group type: EXPERIMENTAL
Intervention: PEEP 10 mbar
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PEEP 5 mbar
Number of subjects: 33

Group type: COMPARATOR
Intervention: PEEP 0 mbar
Number of subjects: 33
Study: 30407354

Group type: EXPERIMENTAL
Intervention: Shuganjianpihuatanxingqi decoction (SD)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 27012938

Group type: EXPERIMENTAL
Intervention: 9 simulation sessions over 1 year (experimental group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 3 simulation sessions over 1 year (control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-assessment of perceived impact of simulations on clinical practice
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Detection of post-traumatic stress disorder by self-assessment questionnaire on the 7th day and after 1 month
Number of subjects: 48
Study: 25690866

Group type: EXPERIMENTAL
Intervention: Modified Mediterranean-type diet with fat modification (canola oil, walnuts, walnut oil) and two portion-controlled sweet daily snacks for 12 weeks.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waiting-list control group (no intervention).
Number of subjects: 100
Study: 22652582

Group type: EXPERIMENTAL
Intervention: PCV7 (1.0 mL)
Number of subjects: 181

Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 181
Study: 20634898

Group type: EXPERIMENTAL
Intervention: Conscious conflict (weakly masked primes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unconscious conflict (strongly masked primes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18380559

Group type: EXPERIMENTAL
Intervention: PRP + beta-TCP + GTR
Number of subjects: 28

Group type: COMPARATOR
Intervention: beta-TCP + GTR
Number of subjects: 28
Study: 16002808

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine supplementation (2.6 g choline/d)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (1.5 g choline) on the first day of supplementation
Number of subjects: 26
Study: 12208795

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 12 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Long-term simvastatin treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-fat meal and glucose alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-fat meal plus glucose
Number of subjects: 50
Study: 10626570

Group type: EXPERIMENTAL
Intervention: Iodine supplementation with tablets, average dose 175 microg K-Iodide/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-iodine-supplemented group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Smoker's newborns
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neonatal TSH screening
Number of subjects: 100
Study: 8554943

Group type: EXPERIMENTAL
Intervention: Pancopride 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancopride 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1782064

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 20 mg/m2 per day on days 1‐5 and 22‐26 with irradiation on days 2, 5, 9, 16, 23 and 26
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 20 mg cisplatin over 24 h commencing 1 h before each fraction of irradiation on days 1, 4, 8, 11, 15 and 18
Number of subjects: 55
Study: 6119170

Group type: EXPERIMENTAL
Intervention: Oxatomide (30 mg t.d.s.)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oxatomide
Number of subjects: 63
Study: 30117327

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 39
Study: 31567965

Group type: EXPERIMENTAL
Intervention: Infrared light-emitting diode (LED) treatment for bruxism
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Occlusal splint treatment for bruxism
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (absence of bruxism)
Number of subjects: 76
Study: 28608398

Group type: EXPERIMENTAL
Intervention: Biogran alone (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biogran + autogenous bone graft (1:1) (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Autogenous bone graft alone (Group 3)
Number of subjects: 30
Study: 26528814

Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cathodal stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 22431415

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 79
Study: 21909502

Group type: EXPERIMENTAL
Intervention: Preoperative oral squamous cell carcinoma patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Postoperative oral squamous cell carcinoma patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral squamous cell carcinoma patients (both groups)
Number of subjects: 31
Study: 19678579

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cefalexin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Surgical treatment only
Number of subjects: 90
Study: 17519147

Group type: EXPERIMENTAL
Intervention: Combined contraceptive vaginal ring (CCVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 0
Study: 15553285

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Clearfil SE Bond) with flowable composite (Filtek Flow)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Clearfil SE Bond) without flowable composite
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Total-etch adhesive (Prime&Bond NT) with flowable composite (Filtek Flow)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Total-etch adhesive (Prime&Bond NT) without flowable composite
Number of subjects: 46

Group type: COMPARATOR
Intervention: Overall (both adhesives)
Number of subjects: 46
Study: 11777512

Group type: EXPERIMENTAL
Intervention: Patients with detrusor instability
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (normal urodynamic testing)
Number of subjects: 33
Study: 9847040

Group type: EXPERIMENTAL
Intervention: Avoidance of high-pitched danger-signal tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rating tones throughout avoidance trials
Number of subjects: 0
Study: 7792555

Group type: EXPERIMENTAL
Intervention: Mitral prosthetic implantation (MPI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mitral valve replacement (MVR)
Number of subjects: 12
Study: 2666532

Group type: EXPERIMENTAL
Intervention: Oral piroxicam (17-day course)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Oral steroid CME treatment
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 178
Study: 803203

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 30370681

Group type: EXPERIMENTAL
Intervention: Short intervention targeting psychosomatic care (home visit by a doctor trained in psychosomatic medicine)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 175
Study: 28502503

Group type: EXPERIMENTAL
Intervention: Combined vitamin D (50,000 IU every 2 weeks) + omega-3 fatty acids (1000 mg twice a day)
Number of subjects: 140
Study: 26134988

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve BR03 and B. breve B632 (2 × 10^9 colony-forming units)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 23375799

Group type: EXPERIMENTAL
Intervention: Aquatic Aerobics Group (AAG)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 82
Study: 21641021

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS applied to the right superior temporal gyrus
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied to the left superior temporal gyrus
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 3
Study: 18048644

Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous transplantation
Number of subjects: 0
Study: 16548360

Group type: EXPERIMENTAL
Intervention: Biqi capsule (BC)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Nimesulide tablet (NT)
Number of subjects: 142
Study: 12640286

Group type: EXPERIMENTAL
Intervention: Isometric exercise training program (6 weeks, involving nondominant arms, isometric hand-grip contractions to 25-35% of MVC lasting 40-120 seconds, repetitive squeezing of squash and racquet balls)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Isometric exercise training program (6 weeks)
Number of subjects: 5
Study: 10769442

Group type: EXPERIMENTAL
Intervention: Eversion endarterectomy (EEA)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional thrombendarterectomy (TEA)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Dacron patch
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Duplex-ultrasound
Number of subjects: 600
Study: 8842602

Group type: EXPERIMENTAL
Intervention: Buccal GLP-I tablet (119 nmol)
Number of subjects: 8
Study: 1728930

Group type: EXPERIMENTAL
Intervention: Serum cholesterol levels above 4.65 mmol/L (180 mg/dL)
Number of subjects: 316099

Group type: EXPERIMENTAL
Intervention: Systolic BP above 110 mm Hg
Number of subjects: 316099

Group type: EXPERIMENTAL
Intervention: Diastolic BP above 70 mm Hg
Number of subjects: 316099

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (high quintiles)
Number of subjects: 316099

Group type: EXPERIMENTAL
Intervention: Systolic BP and diastolic BP, serum cholesterol level, and cigarettes per day
Number of subjects: 316099

Group type: EXPERIMENTAL
Intervention: Systolic BP
Number of subjects: 316099
Study: 6360325

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and methyl-CCNU administered in combination, given in discrete 5-day courses at 7-week intervals.
Number of subjects: 645

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 645
Study: 30455531

Group type: EXPERIMENTAL
Intervention: Results-based financing
Number of subjects: 4000000

Group type: EXPERIMENTAL
Intervention: Input-based financing
Number of subjects: 4000000

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4000000
Study: 27548104

Group type: EXPERIMENTAL
Intervention: Lenvatinib (24 mg once daily)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 24674853

Group type: EXPERIMENTAL
Intervention: Park director (PD) intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Park director and park advisory board (PD+PAB) intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 50
Study: 22208555

Group type: EXPERIMENTAL
Intervention: Mixed-grain diet for 9 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular diet for 9 weeks
Number of subjects: 0
Study: 20466742

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 21
Study: 18552625

Group type: EXPERIMENTAL
Intervention: BPC plus wellness training (WT)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Basic primary care (BPC)
Number of subjects: 309
Study: 15791501

Group type: EXPERIMENTAL
Intervention: Clodronate 400 mg; 1200 mg/day (p.o.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No bisphosphonates treatment
Number of subjects: 16
Study: 12763321

Group type: EXPERIMENTAL
Intervention: High contrast visual transients appearing at various times with respect to the target change.
Number of subjects: 8
Study: 10963288

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 759
Study: 9421740

Group type: EXPERIMENTAL
Intervention: Extracorporeal whole body hyperthermia (EWBH) at 41 degrees C
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Extracorporeal whole body hyperthermia (EWBH) at 42 degrees C
Number of subjects: 6
Study: 8103581

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HMPAO-SPECT
Number of subjects: 10

Group type: COMPARATOR
Intervention: FDG-PET and HMPAO-SPECT
Number of subjects: 10
Study: 2937673

Group type: EXPERIMENTAL
Intervention: Sicorten cream
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Sicorten ointment
Number of subjects: 247

Group type: COMPARATOR
Intervention: Sicorten creams and ointments
Number of subjects: 247
Study: 30280658

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg IV every 2 weeks for up to 12 months)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo (matching placebo every 2 weeks for up to 12 months)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study: 26235391

Group type: EXPERIMENTAL
Intervention: CPAP of 10 cmH2 O during pre-oxygenation and induction of anaesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FIO2 of 1.0 during emergence
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FIO2 of 0.31 during emergence
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with no CPAP and FIO2 of 1.0 during emergence
Number of subjects: 40
Study: 24759202

Group type: EXPERIMENTAL
Intervention: Highly structured planned rest protocol with visitor and healthcare personnel restrictions
Number of subjects: 52

Group type: COMPARATOR
Intervention: Simple planned rest period without restrictions
Number of subjects: 52
Study: 22497533

Group type: EXPERIMENTAL
Intervention: Long-acting beta-agonists (LABA)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 376
Study: 20674826

Group type: EXPERIMENTAL
Intervention: pC1‐INH concentrate (Berinert) at single intravenous doses of 10 or 20 U/kg body weight
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 18715405

Group type: EXPERIMENTAL
Intervention: 3.75 mg of leuprorelin acetate (3-4 weeks)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 3 mg of cetrorelix (4-7 days)
Number of subjects: 106
Study: 15916052

Group type: EXPERIMENTAL
Intervention: Ivermectin (78 cases)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Albendazole (33 cases)
Number of subjects: 697
Study: 12859157

Group type: EXPERIMENTAL
Intervention: Alternating therapy (regimen C)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard of care (regimen A and B)
Number of subjects: 161
Study: 10368202

Group type: EXPERIMENTAL
Intervention: Topical vasoactive cream (aminophylline, isosorbide dinitrate, co-dergocrine mesylate)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo cream (no pharmacologically active ingredients)
Number of subjects: 14
Study: 8721690

Group type: EXPERIMENTAL
Intervention: Angio-Seal hemostasis device
Number of subjects: 68
Study: 1997243

Group type: EXPERIMENTAL
Intervention: Repair and augmentation of the ACL with an iliotibial strip
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Repair without augmentation
Number of subjects: 156

Group type: COMPARATOR
Intervention: Nonsurgical ACL treatment
Number of subjects: 156
Study: 6382700

Group type: EXPERIMENTAL
Intervention: Team care
Number of subjects: 130

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 130
Study: 31451579

Group type: EXPERIMENTAL
Intervention: Clobazam (GABAA modulator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arbaclofen (GABAB modulator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28974349

Group type: EXPERIMENTAL
Intervention: Reduced-dose ICS/LABA
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Stable ICS/LABA
Number of subjects: 459

Group type: COMPARATOR
Intervention: LABA-step-off (ICS alone)
Number of subjects: 459
Study: 26489028

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous cyclophosphamide (CYC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral mycophenolate mofetil (MMF)
Number of subjects: 100
Study: 24338058

Group type: EXPERIMENTAL
Intervention: NMES (5 Hz, 4 pulses at 500 μs)
Number of subjects: 19

Group type: COMPARATOR
Intervention: ACT (30% PVo2max)
Number of subjects: 19

Group type: COMPARATOR
Intervention: PAS (resting)
Number of subjects: 19
Study: 22095616

Group type: EXPERIMENTAL
Intervention: Right ventricular (RV) pacing
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Echo-guided cardiac resynchronisation (CRT) pacing
Number of subjects: 171

Group type: COMPARATOR
Intervention: Non-responders group
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: CRT mode
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Echo-optimised CRT
Number of subjects: 171
Study: 20584348

Group type: EXPERIMENTAL
Intervention: Prednisolone-treated group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 17115180

Group type: EXPERIMENTAL
Intervention: Glutamine (0.125 g kg body mass(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hyperoxia (HPG)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hyperoxia (HYP)
Number of subjects: 8
Study: 16372903

Group type: EXPERIMENTAL
Intervention: Hospital screening invitation
Number of subjects: 1200

Group type: COMPARATOR
Intervention: General practitioner screening invitation
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Distance from test provider > 30 minutes
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Lack of time as a reason for non-compliance
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Accompaniment to test
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Non-receipt of screening invitation letter
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Prior screening
Number of subjects: 1200
Study: 12133087

Group type: EXPERIMENTAL
Intervention: Crystalloid group (Ringer's solution infusion at 1.5 ml.kg(‐1).h(‐1) from 22:00 h until induction of anaesthesia)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Crystalloid group
Number of subjects: 48
Study: 10201594

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral LASIK
Number of subjects: 357

Group type: COMPARATOR
Intervention: Sequential bilateral LASIK
Number of subjects: 357
Study: 7606406

Group type: EXPERIMENTAL
Intervention: Insitucat valvulotome
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hall valvulotome
Number of subjects: 50
Study: 2222347

Group type: EXPERIMENTAL
Intervention: Maxepa (eicosapentaenoic acid)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: COMPARATOR
Intervention: Aspirin/dipyridamole
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Maxepa
Number of subjects: 108
Study: 658870

Group type: EXPERIMENTAL
Intervention: etozolin
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 31833224

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 31
Study: 31096728

Group type: EXPERIMENTAL
Intervention: General anesthesia (Group G)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Spinal anesthesia (Group S)
Number of subjects: 80
Study: 28272120

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combination therapy (Imipramine + Pregabalin)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Imipramine (monotherapy)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pregabalin (monotherapy)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 47
Study: 25772953

Group type: EXPERIMENTAL
Intervention: Topical application of Tranexamic acid (2.5 g in 250 ml normal saline)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study: 23370316

Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m initially, 250 mg/m weekly thereafter) plus Bevacizumab (15 mg/kg) for six cycles combined with Paclitaxel (200 mg/m) and Carboplatin (AUC 6) for six cycles
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m initially, 250 mg/m weekly thereafter) plus Bevacizumab (15 mg/kg) for three cycles combined with Paclitaxel (200 mg/m) and Carboplatin (AUC 6) for three cycles
Number of subjects: 121
Study: 21330337

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy (BFHX)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy (FHX)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (both groups)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Surgical salvage (both groups)
Number of subjects: 26
Study: 19372349

Group type: EXPERIMENTAL
Intervention: Trachlight (TL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flexible fiberoptic bronchoscope (FOB)
Number of subjects: 20